Related Experiment Video
Updated: May 31, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cardiac dysfunction after cancer treatment
Michael S Ewer1, Sandra M Swain, Daniela Cardinale
1Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mewer@mdanderson.org
Abstract:
Onco-cardiology is an evolving discipline that requires the consideration of cardiotoxicity in preclinical, clinical,and therapeutic aspects of protocol development,treatment, and surveillance of patients who have undergone interventions using cardiotoxic agents. Only then can we foster new ways to maximize survival while keeping cardiac damage within acceptable limits. It is to this end that our working together has brought us to our present understanding. In the future, we may expect onco-cardiology to play an even greater role in the care of cancer patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Coronary Artery Disease III: Clinical Manifestations